Your browser doesn't support javascript.
loading
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
Weber, Jeffrey S; Schadendorf, Dirk; Del Vecchio, Michele; Larkin, James; Atkinson, Victoria; Schenker, Michael; Pigozzo, Jacopo; Gogas, Helen; Dalle, Stéphane; Meyer, Nicolas; Ascierto, Paolo A; Sandhu, Shahneen; Eigentler, Thomas; Gutzmer, Ralf; Hassel, Jessica C; Robert, Caroline; Carlino, Matteo S; Di Giacomo, Anna Maria; Butler, Marcus O; Muñoz-Couselo, Eva; Brown, Michael P; Rutkowski, Piotr; Haydon, Andrew; Grob, Jean-Jacques; Schachter, Jacob; Queirolo, Paola; de la Cruz-Merino, Luis; van der Westhuizen, Andre; Menzies, Alexander M; Re, Sandra; Bas, Tuba; de Pril, Veerle; Braverman, Julia; Tenney, Daniel J; Tang, Hao; Long, Georgina V.
Afiliação
  • Weber JS; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY.
  • Schadendorf D; Department of Dermatology, University of Essen and the German Cancer Consortium, Partner Site, Essen, Germany.
  • Del Vecchio M; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Larkin J; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Atkinson V; Division of Cancer Services, Gallipoli Medical Research Foundation and Princess Alexandra Hospital, University of Queensland, Brisbane, Queensland, Australia.
  • Schenker M; Oncology Center Sf Nectarie Ltd, Craiova, Romania.
  • Pigozzo J; Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.
  • Gogas H; National and Kapodistrian University of Athens, Athens, Greece.
  • Dalle S; Hospices Civils de Lyon, Lyon, France.
  • Meyer N; Institut Universitaire du Cancer and CHU, Toulouse, France.
  • Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
  • Sandhu S; Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, Victoria, Australia.
  • Eigentler T; Universitätsklinikum und Medizinische Fakultät Tübingen, Tübingen, and Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Dermatology, Venerology and Allergology, Berlin, Germany.
  • Gutzmer R; Medizinische Hochschule Hannover, Hannover, and Mühlenkreiskliniken Minden, Ruhr-Universität Bochum, Bochum, Germany.
  • Hassel JC; Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
  • Robert C; Gustave Roussy and Paris-Saclay University, Villejuif Cedex, France.
  • Carlino MS; Westmead and Blacktown Hospitals, University of Sydney, Melanoma Institute Australia, Sydney, New South Wales, Australia.
  • Di Giacomo AM; Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy.
  • Butler MO; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Muñoz-Couselo E; Vall d'Hebron University, Barcelona, Spain.
  • Brown MP; Cancer Trials Unit, Royal Adelaide Hospital, and School of Medicine, The University of Adelaide, Adelaide, Australia.
  • Rutkowski P; Maria Sklodowska-Curie National Institute of Oncology, Warsaw, Poland.
  • Haydon A; The Alfred Hospital, Monash University, Melbourne, Australia.
  • Grob JJ; Department of Dermatology, Aix-Marseille University, Hôpital de la Timone, Marseille, France.
  • Schachter J; Sheba Medical Center, IEO European Institute of Oncology, Tel-Hashomer, Israel.
  • Queirolo P; IEO European Institute of Oncology, IRCCS, Milan, Italy.
  • de la Cruz-Merino L; IRCCS San Martino, Genova, Italy.
  • van der Westhuizen A; Department of Clinical Oncology, Hospital University Virgen Macarena, Seville, Spain.
  • Menzies AM; Calvary Mater Newcastle Hospital and University of Newcastle. Waratah, New South Wales, Australia.
  • Re S; Melanoma Institute Australia, University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.
  • Bas T; Bristol Myers Squibb Company, Princeton, NJ.
  • de Pril V; Bristol Myers Squibb Company, Princeton, NJ.
  • Braverman J; Bristol Myers Squibb Company, Princeton, NJ.
  • Tenney DJ; Bristol Myers Squibb Company, Princeton, NJ.
  • Tang H; Bristol Myers Squibb Company, Princeton, NJ.
  • Long GV; Bristol Myers Squibb Company, Princeton, NJ.
J Clin Oncol ; 41(3): 517-527, 2023 01 20.
Article em En | MEDLINE | ID: mdl-36162037
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Ipilimumab / Nivolumabe / Melanoma Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: J Clin Oncol Ano de publicação: 2023 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Ipilimumab / Nivolumabe / Melanoma Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: J Clin Oncol Ano de publicação: 2023 Tipo de documento: Article País de publicação: Estados Unidos